Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization - PubMed (original) (raw)
Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization
J S Boyle et al. Int Immunol. 1997 Dec.
Abstract
We examined the role of the cellular localization of antigen on the immune response after DNA immunization of mice with three forms of ovalbumin (OVA). DNA encoding OVA which was secreted (sOVA) generated 10- to 100-fold higher IgG responses with 50-and 100-fold higher levels of IgG1 than the cytoplasmic (cOVA) or membrane bound (mOVA) forms. An IgG2a predominance was seen only in cOVA and mOVA immunized mice. Although the antibody response was CD4+ T cell dependent, the differences in the antibody response could not be compensated for by provision of excess CD4+ T cell help in TCR transgenic mice. Together with our hapten-carrier studies, this would indicate that membrane or intracellular localization limits the availability of antigen for B cell priming which affects the magnitude and form of the antibody response. Surprisingly, stronger cytotoxic T lymphocyte (CTL) responses were generated for sOVA or mOVA than for cOVA via intramuscular (i.m.) injection. Since a cytoplasmic antigen should have best access to the canonical class I pathway for antigen presentation, our results indicate that priming of CTL responses after i.m. DNA immunization is probably by cross-presentation of antigen by non-transfected professional antigen-presenting cells. In contrast, intradermal immunization with cOVA produced optimal CTL responses but, as with mOVA, suboptimal antibody responses. This, together with our ex vivo RT-PCR analysis showing similar mRNA levels from all three constructs 7 days post-immunization, argues against the differential CTL response for i.m. injection to be due to dose.
Similar articles
- Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT, Umetsu DT, DeKruyff RH, Levy S. Maecker HT, et al. J Immunol. 1998 Dec 15;161(12):6532-6. J Immunol. 1998. PMID: 9862678 - Subcellular Localization of Antigen in Keratinocytes Dictates Delivery of CD4+ T-cell Help for the CTL Response upon Therapeutic DNA Vaccination into the Skin.
Bąbała N, Bovens A, de Vries E, Iglesias-Guimarais V, Ahrends T, Krummel MF, Borst J, Bins AD. Bąbała N, et al. Cancer Immunol Res. 2018 Jul;6(7):835-847. doi: 10.1158/2326-6066.CIR-17-0408. Epub 2018 May 15. Cancer Immunol Res. 2018. PMID: 29764836 - Revealing the potential of DNA-based vaccination: lessons learned from the hepatitis B virus surface antigen.
Schirmbeck R, Reimann J. Schirmbeck R, et al. Biol Chem. 2001 Apr;382(4):543-52. doi: 10.1515/BC.2001.068. Biol Chem. 2001. PMID: 11405219 Review. - DNA immunization: mechanistic studies.
Whitton JL, Rodriguez F, Zhang J, Hassett DE. Whitton JL, et al. Vaccine. 1999 Mar 26;17(13-14):1612-9. doi: 10.1016/s0264-410x(98)00418-6. Vaccine. 1999. PMID: 10194813 Review.
Cited by
- Duck CD40L as an adjuvant enhances systemic immune responses of avian flavivirus DNA vaccine.
Huang J, Luo G, Wang W, Lu Y, Wang M, Liu M, Zhu D, Chen S, Zhao X, Yang Q, Wu Y, Zhang S, Ou X, Tian B, Sun D, He Y, Wu Z, Cheng A, Jia R. Huang J, et al. NPJ Vaccines. 2024 Aug 1;9(1):135. doi: 10.1038/s41541-024-00926-9. NPJ Vaccines. 2024. PMID: 39085226 Free PMC article. - mRNA vaccine designs for optimal adjuvanticity and delivery.
Mochida Y, Uchida S. Mochida Y, et al. RNA Biol. 2024 Jan;21(1):1-27. doi: 10.1080/15476286.2024.2333123. Epub 2024 Mar 26. RNA Biol. 2024. PMID: 38528828 Free PMC article. Review. - mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response.
Scaria PV, Roth N, Schwendt K, Muratova OV, Alani N, Lambert LE, Barnafo EK, Rowe CG, Zaidi IU, Rausch KM, Narum DL, Petsch B, Duffy PE. Scaria PV, et al. NPJ Vaccines. 2024 Jan 6;9(1):9. doi: 10.1038/s41541-023-00783-y. NPJ Vaccines. 2024. PMID: 38184666 Free PMC article. - Caveats of Using Overexpression Approaches to Screen Cellular Host IFITM Proteins for Antiviral Activity.
Meischel T, Fritzlar S, Villalón-Letelier F, Smith JM, Brooks AG, Reading PC, Londrigan SL. Meischel T, et al. Pathogens. 2023 Mar 27;12(4):519. doi: 10.3390/pathogens12040519. Pathogens. 2023. PMID: 37111405 Free PMC article. - Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy.
Franke AC, Hardet R, Prager L, Bentler M, Demeules M, John-Neek P, Jäschke NM, Ha TC, Hacker UT, Adriouch S, Büning H. Franke AC, et al. Mol Ther Methods Clin Dev. 2023 Mar 21;29:238-253. doi: 10.1016/j.omtm.2023.03.010. eCollection 2023 Jun 8. Mol Ther Methods Clin Dev. 2023. PMID: 37090479 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials